This notice corrects presentation and textual errors in a PLOS One article evaluating the risk of hepatitis B virus (HBV) reactivation during treatment of lymphoma patients who were HBsAg- and HBV DNA–negative at baseline. The corrections address a redundant percent sign in Table 1 and incorrect sentences in the Abstract and Results sections related to gender and treatment-duration analyses. The publisher issued the correction, supplied an updated Table 1 image, and apologized for the errors.
In the originally revised Table 1, a percentage sign (%) already appears in the table header (first row). The corrected table removes a redundant “%” that had been included in the revised data for the duration-of-treatment rows. The correct version of Table 1 has been provided by the publisher as an image and as a downloadable TIFF.
The final sentence of the Results subsection of the Abstract was amended. The corrected sentence reads: Conversely, no statistically significant differences in HBV reactivation rates were observed between patients of different genders (P = 0.637, OR = 0.855) or across varying treatment durations (P = 0.837).
This correction clarifies that, according to the study data as presented, neither patient gender nor the duration categories analyzed were associated with statistically significant differences in HBV reactivation rates.
The paragraph reporting the impact of treatment duration on HBV reactivation was corrected as follows.
Because each group with treatment duration exceeding 30 months contained fewer than 20 patients, those groups were excluded from intergroup comparisons of treatment durations. With those longer-duration groups excluded, there was no statistically significant difference in the incidence of HBV reactivation among lymphoma patients across the evaluated treatment-duration categories (P = 0.837).
Except for the 24–27 months treatment interval, in which no HBV reactivation events were reported, HBV reactivation events occurred across the other evaluated time intervals. Among patients who experienced HBV reactivation, the highest frequency (3.41%) was observed during the 15–18 months treatment period; that finding was based on 3 cases. By contrast, 14 cases of HBV reactivation (2.71%) occurred during the 3–6 months treatment period. These figures are presented in the corrected Table 1.
Gender comparison: no statistically significant difference in HBV reactivation rates (P = 0.637; OR = 0.855) as reported in the corrected Abstract.
Treatment-duration comparison: no statistically significant difference across treated duration groups included in the analysis (P = 0.837). Groups with >30 months of treatment were excluded from intergroup comparisons due to small numbers (<20 patients per group).
Timing of events: HBV reactivation events were recorded in most treatment-duration intervals except 24–27 months. The highest reported frequency was 3.41% during 15–18 months (3 cases). The 3–6 months interval accounted for the largest absolute number of cases reported (14 cases; 2.71%).
These corrected counts and percentages derive from the study data as presented in the corrected Table 1; the correction notice supplies the updated table image.
The publisher apologizes for the errors and has made the corrected Table 1 available as images (PNG and TIFF). The correction notice references the original research article: Chen L, Lu Z, Zhang X, Lai J, Huang G, Zheng Y. Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients. PLoS One. 2025;20(9):e0332421. The correction itself is cited as: The PLOS One Staff (2026) Correction: Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients. PLoS One 21(8): e0356789.
This correction addresses presentation and textual errors only. It does not report additional analyses, changes to the study methodology, or new clinical recommendations. Where the correction omits further detail (for example, subgroup sizes by each treatment-duration interval other than the statement about >30 months groups), those specifics were not reported in the correction notice.